Pacira publishes two-year Phase 1 data for knee OA gene therapy
Tweet Send to a Friend
Pacira BioSciences (NASDAQ: PCRX) announced the publication of two-year Phase 1 clinical trial results for its investigational gene therapy PCRX-201 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
